Sergio G. Garcia , Marta Clos-Sansalvador , Marta Sanroque-Muñoz , Linrong Pan , Marcella Franquesa
{"title":"Functional and potency assays for mesenchymal stromal cell–extracellular vesicles in kidney disease","authors":"Sergio G. Garcia , Marta Clos-Sansalvador , Marta Sanroque-Muñoz , Linrong Pan , Marcella Franquesa","doi":"10.1016/j.cophys.2024.100746","DOIUrl":null,"url":null,"abstract":"<div><p>Kidney diseases pose a significant challenge, lacking effective therapies. Extracellular vesicle (EV)-based therapies have emerged as a novel advanced therapeutic. Particularly, mesenchymal stromal cells (MSC) and their EV are being explored as potential candidates. While MSC-EV therapeutics offer promise, there is a lack of widely standardized potency tests to assess EV effectiveness. Tailoring potency assessment in kidney diseases requires considering multifactorial effects and may necessitate a combination of multiple assays to recapitulate EV function. The design of a matrix of assays will be specific for the chosen disease and will involve specific molecular mechanisms and biological processes. This review highlights recent MSC-EV functional assays focused on modeling kidney disease mechanisms of action.</p></div>","PeriodicalId":52156,"journal":{"name":"Current Opinion in Physiology","volume":"38 ","pages":"Article 100746"},"PeriodicalIF":2.5000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Physiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468867324000129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Kidney diseases pose a significant challenge, lacking effective therapies. Extracellular vesicle (EV)-based therapies have emerged as a novel advanced therapeutic. Particularly, mesenchymal stromal cells (MSC) and their EV are being explored as potential candidates. While MSC-EV therapeutics offer promise, there is a lack of widely standardized potency tests to assess EV effectiveness. Tailoring potency assessment in kidney diseases requires considering multifactorial effects and may necessitate a combination of multiple assays to recapitulate EV function. The design of a matrix of assays will be specific for the chosen disease and will involve specific molecular mechanisms and biological processes. This review highlights recent MSC-EV functional assays focused on modeling kidney disease mechanisms of action.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
